|Bid||451.01 x 900|
|Ask||455.00 x 900|
|Day's range||445.15 - 465.79|
|52-week range||271.37 - 518.00|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||24.35|
|Earnings date||04 May 2020 - 10 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||475.00|
Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
The U.S. government and Senate reached an agreement to inject $2 trillion of stimulus to boost the U.S. economy amid the coronavirus-induced turmoil.
The Zacks Analyst Blog Highlights: Calix, CBIZ, The Ensign Group, Regeneron Pharmaceuticals and Turning Point Brands
Low-volatility stocks tend to hold up better in tough times. More interestingly, these stocks have done better over longer periods of time, even before the coronavirus-induced market crash.
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.
Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.
Shares of Moderna soared higher after the company dosed a patient with a vaccine against the novel coronavirus in the Phase 1 study. This, calls for investing in companies racing to develop a vaccine against COVID-19
Though most stocks in the S&P 500 ETF portfolio are in red from the year-to-date look, there are a few that are standing tall in the ongoing market turmoil.